Patients who receive a blood stem cell transplant from a donor outside of their family to treat leukemia and other blood diseases are more likely to have graft failure but less likely to experience graft-versus-host disease, a condition caused by the donor cells attacking the recipient's body, if the transplanted blood cells come directly from a donor's bone marrow, rather than from blood stem cells circulating in the donor's bloodstream (PBSCs), according to new research.
Culture
CHICAGO (December 12, 2011) -- A new study finds that patients who are moved into isolation during a hospital stay are nearly twice as likely to develop delirium, a potentially dangerous change in mental status that often affects hospital patients. Patients who began their stay in isolation were not at increased risk.
Baltimore, MD – December 12, 2011. Researchers from the University of Maryland School of Medicine and the Baltimore VA Medical Center have launched a study of exercise and computerized memory training to see if those activities may help people with Parkinson's disease prevent memory changes. The type of memory that will be examined is known as "executive function;" it allows people to take in information and use it in a new way.
COLUMBUS, Ohio – Older people with acute myeloid leukemia and normal looking chromosomes in their cancer cells have a higher risk of recurrence if they have mutations in a gene called ASXL1, according to a new study by researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).
CHICAGO (December 12, 2011) -- A new study finds that patients who are moved into isolation during a hospital stay are nearly twice as likely to develop delirium, a potentially dangerous change in mental status that often affects hospital patients. Patients who began their stay in isolation were not at increased risk.
DETROIT – Researchers at Henry Ford Hospital have found that one-quarter of severe asthma attacks could be prevented if only patients consistently took their medication as prescribed.
Moreover, an asthma attack was only significantly reduced when patients used at least 75 percent of their prescribed dose, according to the study.
Patients often poorly take their medication based on the onset and degree of symptoms.
DAEGU, SOUTH KOREA—Participation in horticultural activities can improve confidence and social skills, cultivate a positive attitude, and rejuvenate the mind and body. Many studies have emphasized the effects of horticultural activities in relation to physical and psychological rehabilitation, but few have considered the influence of these types of activities on mentally challenged people's autonomic nervous system (ANS) and on the stress hormone cortisol.
SAN DIEGO -- In a major advance in treatment, a multicenter study found that ruxolinitib did a better job than off-label chemotherapy drugs reducing the terrible symptoms associated with myelofibrosis, including pain, enlarged spleen, anemia, fever, chills, fatigue, and weight loss. The results were presented today at the annual meeting of the American Society of Hematology and Oncology in San Diego.
Patients with life-threatening heart valve disease could be helped with alternative scanning techniques that provide greater insight into the condition.
Researchers from the University of Edinburgh used an imaging technique that could help predict which patients will need open heart surgery to replace their heart valves, and improve treatments to prevent the disease.
(SAN DIEGO, December 10, 2011) – Bleeding and clotting disorders affect a large number of patients annually and, while accurate diagnosis is important, timely and effective treatment for these disorders is key, as they have the potential to quickly become life-threatening. Research examining novel treatment techniques for bleeding and clotting disorders will be presented today at the 53rd Annual Meeting of the American Society of Hematology.
(SAN DIEGO, December 11, 2011) – Lymphoma and myeloma are both malignant diseases that arise from lymphocytes, a subset of blood cells, and commonly involve lymph nodes and the bone marrow. Although considerable progress has been made in the treatment of these diseases, they remain a significant challenge for patients and their hematologists. New research introducing unique treatment approaches and targets for lymphoma and myeloma will be presented today at the 53rd Annual Meeting of the American Society of Hematology.
(SAN DIEGO, December 11, 2011) – Asymptomatic patients diagnosed with nonbulky follicular lymphoma, a slow-growing type of non-Hodgkin lymphoma, have traditionally been watched for signs or symptoms of disease progression and then treated with a combination of rituximab and chemotherapy or rituximab alone for select cases.
(SAN DIEGO) –– A new treatment using leukemia patients' own infection-fighting cells appears to protect them from infections and cancer recurrence following treatment with fludarabine-based chemotherapy, according to new research from the Perelman School of Medicine at the University of Pennsylvania.
COLUMBUS, Ohio – An interim analysis of a phase Ib/II clinical trial indicates that a novel experimental agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated in patients who have relapsed and are resistant to other therapy. The agent, called PCI-32765, is the first drug designed to target Bruton's tyrosine kinase, a protein essential for CLL-cell survival and proliferation. CLL is the most common form of leukemia, with about 15,000 new cases annually in the U.S. About 4,400 Americans die of the disease each year.
The active ingredient boceprevir has been available since the middle of 2011 as a treatment for chronic hepatitis C of genotype 1. In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined to establish whether boceprevir offers added benefit in comparison with the previous standard therapy.